logo
  Join        Login             Stock Quote

Watch This Stock: FDA Panel To Review On Regeneron’S Arcalyst On Tuesday

 May 04, 2012 02:48 PM
 


(By R. Chandrasekaran) On May 8, Food and Drug Administration's advisory panel will meet to review on Regeneron Pharmaceuticals' (Nasdaq: REGN) drug Arcalyst for preventing gout flares.

In  last November, the company had applied for supplemental Biologics License Application (sBLA) for its drug Arcalyst injection for gout flare prevention in patients beginning with uric acid-lowering treatment.

Generally, gout flares happen in men in the age group of 40 to 60, though there are some instances where it happens for men aged in early 30s. For women, it occurs after the menopause.

It is widely believed that gout attacks are connected with wine and rich food and was generally termed as a rich man's disease. But this has been termed as wrong impression and that even healthy foods could contribute to gout flares. This impression gains ground for the simple reason that most of drinks and foods contain purines, which are grasped and turned into uric acid. Generally, these are removed from the body, but patients suffering from gout flares have reduced capability to remove it. This builds up into the system.

[Related -Regeneron Pharmaceuticals Inc (REGN): Well Positioned To Rival Amgen In Multi-Billion Dollar Cholesterol Drug Market]

Currently, an estimated 8.3 million people in the U.S. seem to have been affected by gout attack. According to an estimate by Decision Resources, drug market size for acute gout will triple to $117 million, and that of the chronic gout to reach $1.83 billion by 2019.

[Related -7 Stocks Set To Surge On Secret Earnings Pattern]

Interestingly, a FDA staff has reportedly commented that Regeneron's Arcalyst may not necessarily offer sufficient benefit to prevent gout attack that is worth in taking side effects risk. But the benefit of the drug in small dimension was indicated.

This will throw an interesting scenario for the advisory panel to decide. There is every chance that the panel voting may be divided.

The latest FDA news seems to have hurt investors' sentiments on the stock as it is trading $2.34 or 1.75 percent lower at $131.58.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageBuffett's Market Indicator Flashes Red, Prepare To Sell

With each passing month, it's becoming evident that the current bull market has slowed from a gallop to a read on...

article imagePBoC joins other major central banks with unconventional monetary policy action

Softer than expected economic growth in China (see discussion) has finally spurred the PBoC into action. read on...

article imageA Buyback Boost?

Are stock buybacks the only thing keeping this bull market read on...

article imageGold Slides On Perfect Storm For Dollar

For all the anticipation surrounding the delivery of the Fed’s statement in the run-up to the September read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.